Vitamin K Administration for Hemorrhagic Stroke
Yes, vitamin K should be administered to patients with hemorrhagic stroke, but ONLY if they are on vitamin K antagonists (VKAs/warfarin) with an elevated INR ≥1.4. For spontaneous hemorrhagic stroke in patients not on anticoagulation, vitamin K has no role and should not be given.
Clinical Algorithm for Vitamin K Use
Step 1: Determine Anticoagulation Status
If patient is on VKA (warfarin):
- Check INR immediately
- If INR ≥1.4: Administer vitamin K 10 mg IV immediately 1, 2
- If INR 1.3-1.9: Consider lower dose PCC (10-20 IU/kg) with vitamin K 2
- If INR <1.3: Vitamin K not indicated
If patient is NOT on anticoagulation:
- Vitamin K has no therapeutic benefit
- Do not administer
Step 2: Dosing and Administration
For VKA-associated hemorrhagic stroke with INR ≥1.4:
- Initial dose: Vitamin K 10 mg IV 1, 2
- Administer concomitantly with prothrombin complex concentrate (PCC), not as monotherapy 1, 2
- Infuse slowly, not exceeding 1 mg per minute 3
Step 3: Monitoring and Redosing
- Recheck INR within 24-48 hours after initial reversal 1
- If INR remains ≥1.4: Redose with vitamin K 10 mg IV 1
- Continue monitoring until INR normalized
Critical Rationale
Why Vitamin K is Essential for VKA-Associated ICH
The evidence strongly supports vitamin K administration because:
Prevents INR rebound: PCC alone provides rapid but temporary reversal. Without vitamin K, INR can rebound within 12-24 hours, leading to hematoma expansion 2. Case reports document clinical deterioration when PCC was given without vitamin K 2.
Ensures durable reversal: Vitamin K takes 6-8 hours to work but provides sustained INR correction by restoring hepatic synthesis of vitamin K-dependent clotting factors 1, 2.
Reduces hematoma expansion: The INCH trial, which demonstrated superiority of 4-factor PCC over FFP, administered vitamin K 10 mg IV to all participants 2. This combination approach (PCC + vitamin K) is associated with reduced hematoma expansion (18.3% vs 27.1% with FFP alone) 2.
Why Vitamin K Has No Role in Non-VKA Hemorrhagic Stroke
For spontaneous intracerebral hemorrhage without anticoagulation:
- No coagulopathy to reverse
- Vitamin K deficiency as a cause of hemorrhagic stroke is essentially limited to breastfeeding infants who did not receive prophylactic vitamin K at birth 4
- In adults without VKA use, vitamin K administration provides no hemostatic benefit
Important Caveats
Do NOT give vitamin K if:
- High suspicion for cerebral venous thrombosis (may worsen thrombosis) 1
- Patient has concurrent life-threatening thrombosis, symptomatic ischemia, or heparin-induced thrombocytopenia—carefully weigh risks/benefits 1
Special consideration for INR >1.7:
- Even in patients selected for endovascular thrombectomy (for ischemic stroke), recent VKA use with INR >1.7 significantly increases symptomatic intracranial hemorrhage risk (adjusted OR 1.88) 5
- This underscores the importance of aggressive reversal in hemorrhagic stroke with elevated INR
Practical Implementation
The combination therapy approach is critical:
- Vitamin K alone is too slow (takes 6-8 hours for effect)
- PCC alone risks rebound (temporary reversal)
- Together they provide both rapid and durable reversal 1, 2
Administer both agents simultaneously or vitamin K as soon as possible after PCC 1. The goal is INR normalization to limit hematoma expansion, which directly impacts mortality and functional outcomes in VKA-associated intracerebral hemorrhage.